CAPA serves as the engine of a high-performance Pharmaceutical Quality System (PQS). It shifts quality management from reactive "firefighting" to a results-oriented strategy that optimizes processes across manufacturing and the global supply chain. Authorities such as the FDA, WHO, EMA, and CDSCO require a robust CAPA system. During GMP inspections, your CAPA records tell the story of your quality culture and your commitment to operational excellence.

This June 2026 notification signals a maturing pharmacovigilance framework. For stakeholders from large-scale manufacturers and CMOs to frontline healthcare providers, the message is clear: scientific justification is the only path to market survival. This article breaks down the ban and explores the strategic shifts necessary for industry compliance.

Pharmaceutical manufacturing serves as the vital backbone of healthcare systems worldwide. It is the engine that ensures that safe, effective, and high-quality medicines are consistently produced and delivered to patients across diverse geographies, socioeconomic strata, and clinical needs.

At Walter Healthcare, we recognize that a tablet is no longer just a carrier for an active pharmaceutical ingredient (API); it is a highly engineered vehicle designed to navigate the complex physiological environment of the gastrointestinal tract, optimize bioavailability, and ensure absolute stability.

Tablets are the most prevalent solid dosage form, accounting for approximately 70% of all dispensed medicines. Their versatility in shape, size, and weight, tailored to the drug and route of administration, offers significant advantages.

This blog develops an insight about theCefpodoxime Proxetil is a prime example, standing out as a vital antibiotic in pediatrics due to its broad-spectrum efficacy, favorable safety profile, and simple dosing regimen. However, transforming the active pharmaceutical ingredient (API) into a stable, palatable, and patient-friendly oral suspension is a significant challenge in pharmaceutical engineering.

In the fast-evolving world of pharmaceutical manufacturing, the operation of evaporation is far more than simple solvent removal. It is a mission-critical, scientifically engineered transformation that directly determines product quality, therapeutic potency, and regulatory success. Achieving precise concentration through controlled evaporation is a cornerstone of product stability, bioavailability, shelf life, and successful downstream processing.

GLP-1 drugs like semaglutide and liraglutide are revolutionizing diabetes and obesity care by enhancing glucose control and driving weight loss. Their complex manufacturing spanning peptide synthesis, formulation, sterile injectables, and cold-chain logistics poses challenges but also opportunities. With global demand soaring and annual sales projected to exceed $100 billion by 2030, supply chain bottlenecks and device shortages remain critical barriers. As patents for blockb